<code id='4F450E2FCF'></code><style id='4F450E2FCF'></style>
    • <acronym id='4F450E2FCF'></acronym>
      <center id='4F450E2FCF'><center id='4F450E2FCF'><tfoot id='4F450E2FCF'></tfoot></center><abbr id='4F450E2FCF'><dir id='4F450E2FCF'><tfoot id='4F450E2FCF'></tfoot><noframes id='4F450E2FCF'>

    • <optgroup id='4F450E2FCF'><strike id='4F450E2FCF'><sup id='4F450E2FCF'></sup></strike><code id='4F450E2FCF'></code></optgroup>
        1. <b id='4F450E2FCF'><label id='4F450E2FCF'><select id='4F450E2FCF'><dt id='4F450E2FCF'><span id='4F450E2FCF'></span></dt></select></label></b><u id='4F450E2FCF'></u>
          <i id='4F450E2FCF'><strike id='4F450E2FCF'><tt id='4F450E2FCF'><pre id='4F450E2FCF'></pre></tt></strike></i>

          entertainment

          entertainment

          author:focus    Page View:852
          Marc Tessier Lavigne (center) retracted two Science papers on the day his resignation as Stanford president takes effect. Mattarella in San Francisco

          After an expansive investigation found manipulated data and other issues with papers co-authored by Stanford’s now ex-president Marc Tessier-Lavigne, the prominent neuroscientist on Thursday retracted two studies published in the journal Science in 2001 — over the objection of a former postdoctoral researcher who played a leading role in both projects.

          The retractions come the same day that Tessier-Lavigne’s resignation as Stanford president takes effect. His departure was prompted by a 95-page report released by a special committee of the university’s Board of Trustees, which recruited outside scientists and a former federal judge to investigate a dozen papers Tessier-Lavigne co-authored between 1999 and 2009, years before becoming the university’s leader.

          advertisement

          The panel concluded that he did not personally engage in scientific misconduct, but it uncovered manipulated data in some studies Tessier-Lavigne had supervised and found that he took insufficient steps to “decisively and forthrightly” correct these studies.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Anesthesiologist group: stop taking Ozempic before surgery
          Anesthesiologist group: stop taking Ozempic before surgery

          EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

          read more
          Naloxone nonprofit donates 200,000 doses after FDA approval
          Naloxone nonprofit donates 200,000 doses after FDA approval

          RiViveisthesecondnaloxoneproducttoreceiveclearancetobesoldoverthecounter.HarmReductionTherapeuticsAn

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          Treeline, Josh Bilenker's next biotech, is cloaked in mystery

          APPhoto/TedS.WarrenJoshBilenker’slastcompany,LoxoOncology,waspurchasedbyEliLillyfor$8billion.Nosurpr